IP Group is an investor focused on turning companies with outstanding innovations into successful businesses.
The Southampton developer has completed a Series A round led by Foresight Ventures following its recent product launch at CES.
"We would like to welcome our new investors to Audioscenic and would also like to say a huge thank you to our existing investors for their past and continued support"
AlbionVC led the investment round with participation from IP Group, Parkwalk, Hostplus, and Oxford Technology and Innovations EIS Fund.
"Citi Markets uses its deep software expertise to move faster and be more competitive. We find value in Diffblue’s auto-generation of test cases, which helps drive test consistency and coverage of our software. This frees up developers to focus on delivering higher quality software, faster – and improves our developers’ experience,"
The financing round was co-led by Lansdowne Partners, Oxford Science Enterprises, and Parkwalk Advisors.
"Global agriculture needs a new Green Revolution if we are to feed the world sustainably. Being able to control weeds is critical to both yield and the cost of production in most crops and new herbicide modes of action are essential. It’s very exciting to see moa starting to play its part in this new revolution by advancing so far in such little time."
The digital healthcare start-up secured backing from IP Group and Parkwalk Advisors to scale operations in Europe and the US.
"However, due to resource costs and poor logistics, current health systems cannot deliver the amount of therapy needed, with significant backlogs, and few patients receiving anywhere near what they require to get better. This is a common problem faced by hundreds of millions of patients around the world, with inefficient care pathways not only costing health systems hundreds of billions of dollars every year, but costing people a chance to live their lives to their full potential."
The financing round was co-led by Tencent and Flerie Invest to support Phase 1b clinical studies and pipeline expansion.
"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."
